Medtronic has delivered four consecutive earnings beats on a foundation of near-perfect financial health metrics, but the stock is in a confirmed technical downtrend, options positioning signals unusual caution at a put/call ratio of roughly 5.7, and sole-source supplier dependencies represent a supply-chain vulnerability that limits conviction to add at current prices.
Thesis pillars
- Consistent Earnings Delivery↓Deteriorating
- Strong Financial Health Score→Stable
- Confirmed Technical Downtrend↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Medtronic plc. (MDT) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $90.96, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers; Thin upside margin: 3.7%.
Medtronic is a global healthcare technology company operating four segments -- Cardiovascular, Neuroscience, Medical Surgical, and Diabetes -- that develop, manufacture and sell implantable and surgical devices such as the Micra leadless pacemaker, Evolut transcatheter aortic... Read more
Hold if already holding. Not a fresh buy at $90.96, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers; Thin upside margin: 3.7%. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.2/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, earnings proximity 65d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
About Medtronic plc.
About Medtronic plc.
Medtronic operates through four segments -- Cardiovascular, Neuroscience, Medical Surgical, and Diabetes -- selling implantable devices such as the Micra leadless pacemaker, Evolut transcatheter aortic valves, and the MiniMed 780G insulin pump system to healthcare systems and patients in more than 150 countries. The company employs over 95,000 full-time workers globally, with 44% based in the U.S. or Puerto Rico, and in May 2025 announced plans to spin off its Diabetes Operating Unit within 18 months.
Medtronic sells its devices principally to hospitals and physicians, who in turn bill third-party payors such as Medicare, Medicaid, comparable non-U.S. government programs, and private insurers, making reimbursement approval a key determinant of product adoption and pricing. The company manufactures most of its products in-house at facilities worldwide, procuring components, raw materials and services -- including sterilization -- from suppliers across many countries, though for certain components it depends on sole suppliers for reasons of quality, cost or availability. Several key products are manufactured or sterilized at a single facility with constrained capacity and limited alternate options. Medtronic supplements internal research and development, which spans hundreds of clinical trials each fiscal year, with investments and collaborations that provide access to new technologies, and it has grown historically through acquisitions across its Cardiovascular, Neuroscience, Medical Surgical and Diabetes businesses.
Show full overview
Medtronic's supply chain carries a sole-source thread that cuts across its four segments: for reasons of quality assurance, cost effectiveness, or availability, certain components, raw materials and services used to manufacture its products come from sole suppliers, and several key products are manufactured or sterilized at a single facility with constrained capacity and limited options for an alternate site. Because approving a replacement manufacturing or sterilization facility takes considerable time under FDA and other regulatory review, a disruption at one of these single-source facilities -- from a natural disaster, regulatory action, or capacity constraint -- could halt production of specific implantable devices faster than Medtronic could requalify a substitute source.
See also: Healthcare · Medical Devices
From Medtronic plc.'s most recent 10-K filing, extracted September 6, 2026.
Recent developments
updated 2026-09-14Recent Developments — Medtronic plc.
Latest news
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - simplywall.st — simplywall.st negative
- NEWS MDT Adds Rem700 Short Action Left Hand to CRBN Rifle Stock Lineup - Outdoor Wire — Outdoor Wire neutral
- NEWS Medtronic PLC $MDT Stock Position Decreased by California State Teachers Retirement System - MarketBeat — MarketBeat negative
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - Sahm — Sahm negative
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - sahmcapital.c — sahmcapital.com negative
Generated 2026-09-14T05:21:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole suppliers10-K Item 1A: 'certain components, raw materials and services needed to manufacture our products are obtained from sole suppliers'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $90.96, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers; Thin upside margin: 3.7%. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $94.28 (+3.6%), stop $87.24 (−4.3%), A.R:R 0.7:1. Score 6.2/10, moderate confidence.
Take-profit target: $94.28 (+3.7% upside). Target $94.28 (+3.6%), stop $87.24 (−4.3%), A.R:R 0.7:1. Stop-loss: $87.24.
Concentration risk — Supplier: sole suppliers; Thin upside margin: 3.7%; Negative momentum.
Medtronic plc. trades at a P/E of 22.4 (forward 14.2). TrendMatrix value score: 6.1/10. Verdict: Hold.
34 analysts cover MDT with a consensus score of 4.0/5. Average price target: $105.
What does Medtronic plc. do?Medtronic is a global healthcare technology company operating four segments -- Cardiovascular, Neuroscience, Medical...
Medtronic is a global healthcare technology company operating four segments -- Cardiovascular, Neuroscience, Medical Surgical, and Diabetes -- that develop, manufacture and sell implantable and surgical devices such as the Micra leadless pacemaker, Evolut transcatheter aortic valves, InterStim neurostimulators, and the MiniMed 780G insulin pump system. The company sells to healthcare systems, physicians and patients in more than 150 countries, employing over 95,000 people, and in May 2025 announced plans to separate its Diabetes Operating Unit into an independent, publicly traded company withi